Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Issues Earnings Results

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74), Yahoo Finance reports. Calliditas Therapeutics AB (publ) had a negative return on equity of 133.08% and a negative net margin of 40.19%. The company had revenue of $28.43 million for the quarter, compared to analyst estimates of $35.78 million.

Calliditas Therapeutics AB (publ) Stock Performance

Shares of NASDAQ:CALT opened at $22.42 on Friday. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $29.30. The company has a 50-day moving average price of $20.60 and a 200 day moving average price of $21.19. The company has a debt-to-equity ratio of 2.89, a quick ratio of 3.08 and a current ratio of 3.13.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price objective on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.